Depression and Pharmacogenetics

Ampong, David Nana

doi:10.1016/j.apnu.2017.10.011

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, our findings should be validated in a larger, longitudinal sample. We also did not consider other mechanisms of drug degradation, such as glucuronidation, drug transport via p-glycoprotein 67 , or additional variables and epigenetic factors that may impact the effects of the drug and the phenotype of the metabolizer 25 .…”

Section: Discussionmentioning

confidence: 99%

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group

Maier,

Borchert,

Neyazi

et al. 2024

Pharmacopsychiatry

View full text Add to dashboard Cite

Background Approximately 15–25% of depressed patients suffer from difficult-to-treat depression (DTD). Patients with DTD require a thorough examination to avoid the oversight of treatable (psychiatric/somatic) comorbidities or (pseudo-)resistance to antidepressant drugs (ADs). Polymorphisms of the cytochrome P450 (CYP) enzymes 2D6 and 2C19, which play a major role in the metabolism of ADs, may contribute to resistance to ADs. Patients with DTD might benefit from electroconvulsive therapy (ECT). Methods We enrolled 109 patients with DTD and 29 untreated depressed controls (UDC). We assessed risk phenotypes, comorbidities, and treatment, including ECT. We also performed pharmacokinetic analyses of CYP2D6 and CYP2C19. Results DTD patients significantly more often suffered from comorbid psychiatric diseases, especially ICD-10: F40-F48 (DTD:40.4%, UDC:17.2%, OR 11.87, p=0.011) than UDC patients. DTD patients receiving ECT were more likely to achieve remission (37.7% vs. 11.8%, OR=3.96, p=0.023). Treatment with ADs did not differ between remitters and non-remitters. No significant differences were observed in the distribution of CYP2D6 and CYP2C19 variants between both groups. Conclusion Patients with DTD appear to experience comorbid neurotic stress and somatoform disorders (ICD-10: F40 – F48) more frequently. Therefore, a comprehensive differential diagnosis is crucial when patients do not respond sufficiently to antidepressant medication. Genotyping CYP2D6 and CYP2C19 should be considered.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group

Maier,

Borchert,

Neyazi

et al. 2024

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…Furthermore, while they may address a current episode of depression, they do not protect against future crises. The treatment of depression has therefore remained a challenge (Ampong, 2018), and according to Park et al (2018), public beliefs about psychiatric disorders, including depression, are important for understanding help-seeking behaviors. All the same, Levi et al (2019), call for further research to appreciate the nexus of tourism and depression.…”

Section: The Impacts Of Tourism On the Wellbeing And Psychology Of Peoplementioning

confidence: 99%

Tourist experience: The catalyst role of tourism in comforting melancholy, or not

Christou

Simillidou

2020

Journal of Hospitality and Tourism Management

View full text Add to dashboard Cite

Depression and Pharmacogenetics

Cited by 2 publications

References 10 publications

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group

Tourist experience: The catalyst role of tourism in comforting melancholy, or not

Contact Info

Product

Resources

About